Sandra Camprubi
Instituto Grifols, S.A.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sandra Camprubi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:25 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT00555555 · Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand PatientsGrifols Biologicals, LLC · terminated · Von Willebrand Disease · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:25 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- 40 citationsRCR 1.7
- 22 citationsRCR 1.1
- α1-Antitrypsin in fibromyalgia: results of a randomized, placebo-controlled, double-blind and crossover pilot trial.Musculoskeletal Care · 20124 citationsRCR 0.2
- A Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of Fibrin Sealant Grifols in Achieving Hemostasis in Pediatric Surgery.J Pediatr Surg · 20241 citationsRCR 0.3